ZGDHu‑1 for cancer therapy (Review)

Liu,Jinlin; Qiu,Liannv; Xia,Jun; Chen,Sufeng; Yu,Xiping; Zhou,Yonglie

doi:10.3892/ol.2017.7096

ZGDHu‑1 for cancer therapy (Review)

Authors:
- Jinlin Liu
- Liannv Qiu
- Jun Xia
- Sufeng Chen
- Xiping Yu
- Yonglie Zhou
View Affiliations

Affiliations: Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
Published online on: September 28, 2017 https://doi.org/10.3892/ol.2017.7096
Pages: 6334-6340
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

N,N'‑di‑(m‑methylphenyl)‑3,6‑dimethyl‑1,4‑dihydro‑1,2,4,5‑tetrazine‑1,4‑dicarboamide (ZGDHu‑1) is a novel tetrazine derivative that was initially designed and produced by Professor W.X. Hu, and which has been reported by our group to exhibit antitumor activity. Accumulating evidence suggests that the anticancer mechanisms of ZGDHu‑1 may be involved indifferent biological activities, particularly in acute myeloid leukemia (AML) cells. At a high concentration, ZGDHu‑1 has been demonstrated to inhibit the proliferation of the leukemia cells by arresting the cell cycle at the G2/M phase, and by inducing cell apoptosis via inducing the accumulation of reactive oxygen species, the translocation of phosphatidylserine across the plasma membrane and the loss of mitochondrial membrane potential. Furthermore, at a low concentration, it was demonstrated to induce the differentiation and degrade the AML1‑eight‑twenty‑one fusion protein in AML cells. Finally, results from a previous study indicate that ZGDHu‑1 is a potential proteasome inhibitor. Overall, our preliminary research suggests that ZGDHu‑1 may be a promising anticancer drug; however, further research is warranted to identify the exact drug target and potential clinical application in leukemia cells or solid tumors. In the present review, the application of ZGDHu‑1 in cancer research, in addition to the specific underlying targets of ZGDHu‑1, are discussed.

View Figures

View References

1	Estey E: Why is progress in acute myeloid leukemia so slow? Semin Hematol. 52:243–248. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lichtenegger FS, Krupka C, Köhnke T and Subklewe M: Immunotherapy for acute myeloid leukemia. Semin Hematol. 52:207–214. 2015. View Article : Google Scholar : PubMed/NCBI
3	Coombs CC, Tallman MS and Levine RL: Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol. 13:305–318. 2016. View Article : Google Scholar : PubMed/NCBI
4	Marucci G: Treatment of pituitary neoplasms with temozolomide: A review. Cancer. 117:4101–4102. 2011. View Article : Google Scholar : PubMed/NCBI
5	Falfushynska HI, Gnatyshyna LL and Stoliar OB: Population-related molecular responses on the effect of pesticides in Carassius auratus gibelio. Comp Biochem Physiol C Toxicol Pharmacol. 155:396–406. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rao GW, Wang C, Wang J, Zhao ZG and Hu WX: Synthesis, structure analysis, antitumor evaluation and 3D-QSAR studies of 3,6-disubstituted-dihydro-1,2,4,5-tetrazine derivatives. Bioorg Med Chem Lett. 23:6474–6480. 2013. View Article : Google Scholar : PubMed/NCBI
7	Nhu D, Duffy S, Avery VM, Hughes A and Baell JB: Antimalarial 3-arylamino-6-benzylamino-1,2,4,5-tetrazines. Bioorg Med Chem Lett. 20:4496–4498. 2010. View Article : Google Scholar : PubMed/NCBI
8	Tabassum S, Parveen M, Ali A, Alama M, Ahmad Anis, UKhan A and Khana RA: Synthesis of Aryl-1,2,4,5-tetrazinane-3-thiones, in vitro DNA binding studies, nuclease activity and its antimicrobial activity. J Mol Structure. 1020:33–40. 2012. View Article : Google Scholar
9	Stanovnik B, Grošelj U and Svete J: 9.12–1,2,4,5-TetrazinesComprehensive Heterocyclic Chemistry III. Katritzky AR, Ramsden CA, Scriven EFV and Taylor RJK: Elsevier; Oxford: pp. 641–714. 2008
10	Rao GW and Hu WX: Synthesis, X-ray crystallographic analysis and antitumor activity of 1-acyl-3,6-disubstituted phenyl-1,4-dihydro-1,2,4,5-tetrazines. Bioorg Med Chem Lett. 15:3174–3176. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rao GW and Hu WX: Synthesis, structure analysis and antitumor activity of 3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg Med Chem Lett. 16:3702–3705. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hu WX, Rao GW and Sun YQ: Synthesis and antitumor activity of s-tetrazine derivatives. Bioorg Med Chem Lett. 14:1177–1181. 2004. View Article : Google Scholar : PubMed/NCBI
13	Qiu LN, Zhou YL, Wang ZN, Huang Q and Hu WX: ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells. Int J Oncol. 41:533–540. 2012. View Article : Google Scholar : PubMed/NCBI
14	Qiu L, Liu J, Wang Z, Hu W, Huang Q and Zhou Y: ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells. Oncol Rep. 34:1239–1248. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chen SF, Xia J, Lv YP, Liu JL, Li WX, Yu XP, Hu WX and Zhou YL: N,N'-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer cells via apoptosis and G2/M cell cycle arrest. Oncol Rep. 33:1915–1921. 2015. View Article : Google Scholar : PubMed/NCBI
16	Xia J, Chen SF, Lv YP, Lu LN, Hu WX and Zhou YL: ZGDHu-1 induces G₂/M phase arrest and apoptosis in Kasumi-1 cells. Mol Med Rep. 11:3398–3404. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhou YL, Lu YP, Hu WX, Qiu LN, Wang WS and Liu JD: Effects of N, N-di-(m-methylphenyl)-3,6-dimethyl-1, 4-dihydro-1,2,4,5-tetrazine-1,4-dicarboxamide (ZGDhu-1) on SHI-1 leukemia cells in vitro. Zhonghua Xue Ye Xue Za Zhi. 27:361–365. 2006.(In Chinese). PubMed/NCBI
18	Zhou YL, Lü YP, Hu WX, Qiu LN, Wang WS, Wu JG and Liu JD: Effects of N, N'-Di-(m-methylphenyi)-3,6-dimethyl-1, 4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide on proliferation, apoptosis and differentiation of NB4 leukemia cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 14:880–886. 2006.(In Chinese). PubMed/NCBI
19	Zhou YL, Hu WX, Lü YP, Qiu LN, Wang WS, Yang ZY, Liu JD and Rao GW: Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo. Yao Xue Xue Bao. 42:26–34. 2007.(In Chinese). PubMed/NCBI
20	Zhou YL, Lü YP, Hu WX, Qiu LN, Wang WS, Liu JD and Wu JG: ZGDHu-1-inducing apoptosis of SHI-1 leukemia cells and its molecular mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15:483–489. 2007.(In Chinese). PubMed/NCBI
21	Zhou YL, Xu WL, Wang ZN, Lü YP and Hu WX: Apoptosis of human lung carcinoma cell line EBC-1 induced by N,N'-di-(m-methylphenyl)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamid e and its molecular mechanism. Zhonghua Zhong Liu Za Zhi. 32:886–891. 2010.(In Chinese). PubMed/NCBI
22	Zhou YL, Chen LC and Lü YP: Inhibition effects of ZGDHu-1 on proteasome in Kasumi-1 cells. Zhonghua Xue Ye Xue Za Zhi. 33:61–63. 2012.(In Chinese). PubMed/NCBI
23	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang Y and Ceng J: A new human acute monocytic leukemia cell line SHI-1 with t (6;11) (q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica. 90:766–775. 2005.PubMed/NCBI
25	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
27	Ferrara F and Del Vecchio L: Acute myeloid leukemia with t(8;21)/AML1/ETO: A distinct biological and clinical entity. Haematologica. 87:306–319. 2002.PubMed/NCBI
28	Murray AW: Recycling the cell cycle: Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
29	Santo L, Siu KT and Raje N: Targeting cyclin-dependent kinases and cell cycle progression in human cancers. Semin Oncol. 42:788–800. 2015. View Article : Google Scholar : PubMed/NCBI
30	Stark GR and Taylor WR: Control of the G2/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
31	Bosman MC, Schuringa JJ and Vellenga E: Constitutive NF-κB activation in AML: Causes and treatment strategies. Crit Rev Oncol Hematol. 98:35–44. 2016. View Article : Google Scholar : PubMed/NCBI
32	Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
33	Baumeister W, Walz J, Zühl F and Seemüller E: The proteasome: Paradigm of a self-compartmentalizing protease. Cell. 92:367–380. 1998. View Article : Google Scholar : PubMed/NCBI
34	Ciechanover A: The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J. 17:7151–7160. 1998. View Article : Google Scholar : PubMed/NCBI
35	Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
36	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
37	Schwartz R and Davidson T: Pharmacology, pharmacokinetics and practical applications of bortezomib. Oncology (Williston Park). 18 14 Suppl 11:S14–S21. 2004.
38	Chen D and Dou QP: The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci. 11:459–470. 2010. View Article : Google Scholar : PubMed/NCBI
39	Chen W, Lee J, Cho SY and Fine HA: Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. 64:3949–3957. 2004. View Article : Google Scholar : PubMed/NCBI
40	Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:957–972. 1997. View Article : Google Scholar : PubMed/NCBI
41	Blagosklonny MV: P53: An ubiquitous target of anticancer drugs. Int J Cancer. 98:161–166. 2002. View Article : Google Scholar : PubMed/NCBI
42	Kalejta RF and Shenk T: Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci USA. 100:pp. 3263–3268. 2003, View Article : Google Scholar : PubMed/NCBI
43	Li B and Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA. 97:pp. 3850–3855. 2000, View Article : Google Scholar : PubMed/NCBI
44	Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:682–685. 1995. View Article : Google Scholar : PubMed/NCBI
45	Chen ZJ: Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 7:758–765. 2005. View Article : Google Scholar : PubMed/NCBI
46	Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L and Stunnenberg HG: PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 17:173–185. 2010. View Article : Google Scholar : PubMed/NCBI
47	Li J, Zhu H, Hu J, Mi J, Chen S, Chen Z and Wang Z: Progress in the treatment of acute promyelocytic leukemia: Optimization and obstruction. Int J Hematol. 100:38–50. 2014. View Article : Google Scholar : PubMed/NCBI
48	Roussel MJ and Lanotte M: Maturation sensitive and resistant t (15;17) NB4 cell lines as tools for APL physiopathology: Nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene. 20:7287–7291. 2001. View Article : Google Scholar : PubMed/NCBI
49	Špaček M: Small molecules in the treatment of chronic lymphocytic leukemia in 2015 and in the near future. Klin Onkol. 28 Suppl 3:3S45–3S49. 2015.(In Czech). View Article : Google Scholar : PubMed/NCBI
50	Huang Y, Wu JZ, Li JY and Xu W: Know the enemy as well as the weapons in hand: The aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia. Am J Cancer Res. 5:2361–2375. 2015.PubMed/NCBI
51	Dighiero G and Hamblin TJ: Chronic lymphocytic leukaemia. Lancet. 371:1017–1029. 2008. View Article : Google Scholar : PubMed/NCBI
52	Buggins AG and Pepper CJ: The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 34:837–842. 2010. View Article : Google Scholar : PubMed/NCBI
53	Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Döhner H, Debatin KM, Stilgenbauer S and Fulda S: A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 69:8977–8986. 2009. View Article : Google Scholar : PubMed/NCBI
54	Pepper C, Hoy T and Bentley DP: Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 76:935–938. 1997. View Article : Google Scholar : PubMed/NCBI
55	Pepper C, Thomas A, Hoy T and Bentley P: Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol. 104:581–588. 1999. View Article : Google Scholar : PubMed/NCBI
56	Molica S, Dattilo A, Giulino C, Levato D and Levato L: Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica. 83:1122–1124. 1998.PubMed/NCBI
57	Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, Hills R, Ward R, Starczynski J, Austen B, et al: Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 112:3807–3817. 2008. View Article : Google Scholar : PubMed/NCBI
58	Anderson MA, Huang D and Roberts A: Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 51:219–227. 2014. View Article : Google Scholar : PubMed/NCBI
59	Yu EM, Kittai A and Tabbara IA: Chronic lymphocytic leukemia: Current concepts. Anticancer Res. 35:5149–5165. 2015.PubMed/NCBI
60	Hallek M: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 90:446–460. 2015. View Article : Google Scholar : PubMed/NCBI
61	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI